OneDigital Investment Advisors LLC Boosts Position in Inozyme Pharma, Inc. (NASDAQ:INZY)

OneDigital Investment Advisors LLC lifted its position in Inozyme Pharma, Inc. (NASDAQ:INZY) by 51.5% during the third quarter, HoldingsChannel reports. The institutional investor owned 20,000 shares of the company’s stock after purchasing an additional 6,800 shares during the period. OneDigital Investment Advisors LLC’s holdings in Inozyme Pharma were worth $105,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Deerfield Management Company L.P. Series C purchased a new stake in Inozyme Pharma in the 2nd quarter worth approximately $52,000. Meeder Asset Management Inc. bought a new position in shares of Inozyme Pharma in the second quarter worth $68,000. Values First Advisors Inc. purchased a new stake in shares of Inozyme Pharma in the second quarter worth $76,000. SG Americas Securities LLC bought a new stake in Inozyme Pharma during the third quarter valued at $81,000. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Inozyme Pharma during the 2nd quarter valued at about $84,000. 88.30% of the stock is currently owned by institutional investors.

Inozyme Pharma Price Performance

Shares of NASDAQ:INZY opened at $2.81 on Friday. The company has a quick ratio of 7.68, a current ratio of 7.68 and a debt-to-equity ratio of 0.51. The stock has a market cap of $180.51 million, a PE ratio of -1.80 and a beta of 1.54. The company’s fifty day moving average is $4.66 and its 200 day moving average is $4.83. Inozyme Pharma, Inc. has a 52 week low of $2.61 and a 52 week high of $7.80.

Inozyme Pharma (NASDAQ:INZY) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.05. Research analysts anticipate that Inozyme Pharma, Inc. will post -1.59 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on INZY. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 target price on shares of Inozyme Pharma in a research note on Wednesday, November 6th. Wedbush restated an “outperform” rating and set a $12.00 price objective (down previously from $15.00) on shares of Inozyme Pharma in a research report on Tuesday, November 5th. Stifel Nicolaus began coverage on shares of Inozyme Pharma in a research report on Thursday, September 12th. They issued a “buy” rating and a $16.00 target price for the company. HC Wainwright restated a “buy” rating and set a $14.00 price target on shares of Inozyme Pharma in a research report on Wednesday, November 6th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $17.00 price objective (up from $16.00) on shares of Inozyme Pharma in a report on Tuesday, August 13th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $15.71.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.